Vonetize. After delay, launch of operations in Russia expected by the end of 2018; the company needs additional sources of funding; acquisition by Desilu Studios is still awaiting completion; target price has been reduced to NIS 1.00. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingVonetize. After delay, launch of operations in Russia expected by the end of 2018; the company needs additional sources of funding; acquisition by Desilu Studios is still awaiting completion; target price has been reduced to NIS 1.00.
Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingKadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.
SAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingSAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85.